Strongbridge Biopharma PLC (NASDAQ:SBBP) posted its quarterly earnings results on Tuesday, May 16th. The biotechnology company reported ($0.33) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.16, MarketWatch Earnings reports.

Strongbridge Biopharma PLC (SBBP) traded down 3.49% during trading on Friday, reaching $4.15. The company had a trading volume of 37,494 shares. The company’s 50-day moving average is $4.47 and its 200 day moving average is $3.62. The firm’s market capitalization is $146.64 million. Strongbridge Biopharma PLC has a 52 week low of $2.00 and a 52 week high of $6.24.

COPYRIGHT VIOLATION WARNING: This article was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at

A number of analysts have issued reports on SBBP shares. Zacks Investment Research raised Strongbridge Biopharma PLC from a “hold” rating to a “buy” rating and set a $4.25 price objective on the stock in a research note on Tuesday, March 7th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Strongbridge Biopharma PLC in a research note on Thursday, March 30th.

Strongbridge Biopharma PLC Company Profile

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Receive News & Stock Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related stocks with our FREE daily email newsletter.